TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Sponsor
Zhongda Hospital
Study ID
NCT04559607
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab: 200mg, iv, Q3W
  • TACE — DEVICE
    TACE if necessary
  • Apatinib — DRUG
    Apatinib: 250m, po, QD

Study Details

The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.

Key Dates

Start date
Sep 11, 2020
Status verified
Dec 2023
Primary completion
Aug 31, 2024
Completion
Jan 31, 2026

Study Design

Enrollment
188 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group: TACE+Camrelizumab+Apatinib
    Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
  • Active Comparator: Control group: TACE
    TACE

Primary Outcome Measure

Progression-free survival (PFS) by investigator [ Time Frame: Up to ~2 years ]

Related Studies